These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17950815)

  • 1. Cost and effectiveness of cardiovascular prevention.
    Boyar A
    Am J Cardiol; 2007 Nov; 100(9):1492-4; author reply 1494-5. PubMed ID: 17950815
    [No Abstract]   [Full Text] [Related]  

  • 2. The things to come of SHAPE: cost and effectiveness of cardiovascular prevention.
    Diamond GA; Kaul S
    Am J Cardiol; 2007 Apr; 99(7):1013-5. PubMed ID: 17398203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Statins in primary prevention - a must for the general practitioner?].
    Zoller M
    Praxis (Bern 1994); 2011 Jul; 100(14):859-60. PubMed ID: 21732299
    [No Abstract]   [Full Text] [Related]  

  • 4. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
    Marshall T
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):523-8. PubMed ID: 16874140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular primary prevention: how high should we set the bar?
    Prasad V; Vandross A
    Arch Intern Med; 2012 Apr; 172(8):656-9; discussion 659. PubMed ID: 22529231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [2008 National Cardiology Guidelines: Prioritization requires consideration to other factors than scientific studies alone].
    Eklund K; Grip L; Israelsson B; Levin LA; Lindahl B; Wallentin L
    Lakartidningen; 2008 May 7-13; 105(19):1408-9; discussion 1409. PubMed ID: 18574983
    [No Abstract]   [Full Text] [Related]  

  • 8. [JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline].
    Lubsen J
    Ned Tijdschr Geneeskd; 2009 Feb; 153(6):216-7. PubMed ID: 19271438
    [No Abstract]   [Full Text] [Related]  

  • 9. Statins for everyone--(even for those at low risk.) Experts are excited, but the question is whether benefits would outweigh costs.
    Duke Med Health News; 2009 Feb; 15(2):1, 11. PubMed ID: 19358321
    [No Abstract]   [Full Text] [Related]  

  • 10. [Polish forum for prevention guidelines on cardiovascular risk assessment].
    Podolec P; Kopeć G; Pajak A; Undas A; Kozek E; Tykarski A; Naruszewicz M; Stańczyk J; Opala G; Godycki-Cwirko M; Rynkiewicz A; Torbicki A; Musiał J
    Kardiol Pol; 2007 Jan; 65(1):100-4. PubMed ID: 17295170
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk assessment for prevention of morbidity and mortality: lessons for pressure ulcer prevention.
    Reynolds TM
    J Tissue Viability; 2008 Nov; 17(4):115-20. PubMed ID: 19061825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economics of cardiovascular disease in the United States.
    Chen J; Rizzo JA
    Crit Care Clin; 2012 Jan; 28(1):77-88, vi. PubMed ID: 22123100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins for millions more?
    Lancet; 2014 Feb; 383(9918):669. PubMed ID: 24560042
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting patients for statin therapy for the primary prevention of vascular events: what is the best approach?
    Mahoney EM
    Circulation; 2010 Oct; 122(15):1446-8. PubMed ID: 20876432
    [No Abstract]   [Full Text] [Related]  

  • 15. Interview: role of managed care in implementing NCEP-ATP III guidelines.
    Carver JC
    Am J Manag Care; 2002 Jul; Suppl Symposium Reporter():7. PubMed ID: 12608153
    [No Abstract]   [Full Text] [Related]  

  • 16. Prescribing statins in general practice: who decides?
    Steel N; Fleetcroft B; Hassan Y
    Br J Gen Pract; 2017 Jun; 67(659):246-247. PubMed ID: 28546390
    [No Abstract]   [Full Text] [Related]  

  • 17. Screening for disease, cost-effectiveness, and guidelines.
    Meyer DL
    Prim Care; 1995 Dec; 22(4):591-9. PubMed ID: 8668731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. By Jove! What is a clinician to make of JUPITER?
    Kaul S; Morrissey RP; Diamond GA
    Arch Intern Med; 2010 Jun; 170(12):1073-7. PubMed ID: 20585074
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study.
    McConnachie A; Walker A; Robertson M; Marchbank L; Peacock J; Packard CJ; Cobbe SM; Ford I
    Eur Heart J; 2014 Feb; 35(5):290-8. PubMed ID: 23839541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost of cardiac arrest in the workplace.
    Ambrose R
    Occup Health Saf; 2004 Sep; 73(9):88, 90, 202. PubMed ID: 15497579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.